There are 10 resources available
Immune-Check Points Inhibitors (ICI) in non-oncogenic addicted mNSCLC
Presenter: Marina Garassino
Session: ESMO Colloquium supported by Lilly Oncology: Biomarker-driven treatment decision in metastatic NSCLC
Resources:
Slides
Webcast
EGFR mutant mNSCLC: Single agent or in combination?
Presenter: Fabrice Barlesi
Session: ESMO Colloquium supported by Lilly Oncology: Biomarker-driven treatment decision in metastatic NSCLC
Resources:
Slides
Webcast
Future development for the use of biomarkers
Presenter: Ross Soo
Session: ESMO Colloquium supported by Lilly Oncology: Biomarker-driven treatment decision in metastatic NSCLC
Resources:
Slides
Webcast
Optimal first-line treatment in mCRPC after either chemo or ARI in mHSPC
Presenter: Cora Sternberg
Session: ESMO Colloquium supported by Astellas - State of the art management of mCPRC
Resources:
Slides
Is there an optimal sequencing strategy in mCRPC?
Presenter: Ben Tran
Session: ESMO Colloquium supported by Astellas - State of the art management of mCPRC
Resources:
Slides
mCRPC definition and benefits of treatment
Presenter: Ravindran Kanesvaran
Session: ESMO Colloquium supported by Astellas - State of the art management of mCPRC
Resources:
Slides
Changing treatment algorithms in mCRPC: Role of PARP inhibitors
Presenter: Arun Azad
Session: ESMO Colloquium supported by Astellas - State of the art management of mCPRC
Resources:
Slides
Immunotherapy in mCRPC management
Presenter: Arun Azad
Session: ESMO Colloquium supported by Astellas - State of the art management of mCPRC
Resources:
Slides
What does liquid biopsy mean?
Presenter: François Clément Bidard
Session: ESMO Colloquium supported by Guardant Health: Liquid biopsy in the management of solid tumours
Resources:
Slides
Use of liquid biopsies in colorectal cancers
Presenter: Takayuki Yoshino
Session: ESMO Colloquium supported by Guardant Health: Liquid biopsy in the management of solid tumours
Resources:
Slides